J E Toblli1, G Cao, G DeRosa, P Forcada. 1. Laboratory of Experimental Medicine, Hospital Alemán, CONICET, Av Pueyrredon 1640, Buenos Aires 1118, Argentina. jtoblli@hospitalaleman.com
Abstract
OBJECTIVE: To determine whether angiotensin converting enzyme inhibition by perindopril can reduce cardiac transforming growth factor beta1 (TGFbeta1) and plasminogen activator inhibitor 1 (PAI-1) and therefore control collagen accumulation in an animal model with the metabolic syndrome such as the obese Zucker rat (OZR). ANIMALS: Male OZR (group 1, n = 10); OZR treated with perindopril (group 2, n = 10); and lean Zucker rats (group 3, n = 10). METHODS: During six months, group 2 received 3 mg/kg/day of perindopril orally and group 1 and group 3 were given a vehicle. Hearts were processed for pathology studies including immunohistochemical analysis with antibodies to PAI-1, TGFbeta1, collagen type I, and collagen type III. RESULTS: Group 2 had lower blood pressure (126.7 (2) v 148.6 (2.7) mm Hg, p < 0.01) than untreated OZR and had decreased cardiac PAI-1 (3.6 (0.4) v 13.5 (1.7)% of positive area/field, p < 0.01), TGFbeta1 in myocytes (0.13 (0.1) v 9.14 (4.7)%/area, p < 0.01) and in interstitium (19.8 (6.8) v 178.9 (27.4) positive cells/area, p < 0.01), collagen I (3 (0.8) v 13.3 (1)%/area, p < 0.01), collagen III (5 (0.6) v 9.5 (0.9)%/area, p < 0.01), and collagen I to collagen III ratio (0.59 (0.13) v 1.40 (0.15) p < 0.01) compared with untreated OZR. CONCLUSION: These results suggest that perindopril reduces cardiac PAI-1 and TGFbeta1 and ameliorates cardiac fibrosis in a rat model with multiple cardiovascular risk factors.
OBJECTIVE: To determine whether angiotensin converting enzyme inhibition by perindopril can reduce cardiac transforming growth factor beta1 (TGFbeta1) and plasminogen activator inhibitor 1 (PAI-1) and therefore control collagen accumulation in an animal model with the metabolic syndrome such as the obese Zuckerrat (OZR). ANIMALS: Male OZR (group 1, n = 10); OZR treated with perindopril (group 2, n = 10); and lean Zucker rats (group 3, n = 10). METHODS: During six months, group 2 received 3 mg/kg/day of perindopril orally and group 1 and group 3 were given a vehicle. Hearts were processed for pathology studies including immunohistochemical analysis with antibodies to PAI-1, TGFbeta1, collagen type I, and collagen type III. RESULTS: Group 2 had lower blood pressure (126.7 (2) v 148.6 (2.7) mm Hg, p < 0.01) than untreated OZR and had decreased cardiac PAI-1 (3.6 (0.4) v 13.5 (1.7)% of positive area/field, p < 0.01), TGFbeta1 in myocytes (0.13 (0.1) v 9.14 (4.7)%/area, p < 0.01) and in interstitium (19.8 (6.8) v 178.9 (27.4) positive cells/area, p < 0.01), collagen I (3 (0.8) v 13.3 (1)%/area, p < 0.01), collagen III (5 (0.6) v 9.5 (0.9)%/area, p < 0.01), and collagen I to collagen III ratio (0.59 (0.13) v 1.40 (0.15) p < 0.01) compared with untreated OZR. CONCLUSION: These results suggest that perindopril reduces cardiac PAI-1 and TGFbeta1 and ameliorates cardiac fibrosis in a rat model with multiple cardiovascular risk factors.
Authors: K Higashiura; N Ura; T Takada; Y Li; T Torii; N Togashi; M Takada; H Takizawa; K Shimamoto Journal: Am J Hypertens Date: 2000-03 Impact factor: 2.689
Authors: A K Zaman; S Fujii; H Sawa; D Goto; N Ishimori; K Watano; T Kaneko; T Furumoto; T Sugawara; I Sakuma; A Kitabatake; B E Sobel Journal: Circulation Date: 2001-06-26 Impact factor: 29.690
Authors: Yaqin Liang; Anna L Lang; Jian Zhang; Jing Chen; Kai Wang; Liya Chen; Juliane I Beier; Yan Qian; Lu Cai Journal: Chem Res Toxicol Date: 2018-05-10 Impact factor: 3.739
Authors: Thomas J Wang; Martin G Larson; Emelia J Benjamin; Deborah A Siwik; Radwan Safa; Chao-Yu Guo; Diane Corey; Johan Sundstrom; Douglas B Sawyer; Wilson S Colucci; Ramachandran S Vasan Journal: Am Heart J Date: 2007-08 Impact factor: 4.749
Authors: Teresa Salvatore; Pia Clara Pafundi; Raffaele Galiero; Gaetana Albanese; Anna Di Martino; Alfredo Caturano; Erica Vetrano; Luca Rinaldi; Ferdinando Carlo Sasso Journal: Front Med (Lausanne) Date: 2021-06-30